| __timestamp | Axsome Therapeutics, Inc. | Bausch Health Companies Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4279200 | 246000000 |
| Thursday, January 1, 2015 | 6776987 | 582800000 |
| Friday, January 1, 2016 | 21199860 | 455000000 |
| Sunday, January 1, 2017 | 19957616 | 366000000 |
| Monday, January 1, 2018 | 23495055 | 414000000 |
| Tuesday, January 1, 2019 | 53647067 | 471000000 |
| Wednesday, January 1, 2020 | 70244579 | 452000000 |
| Friday, January 1, 2021 | 58060725 | 465000000 |
| Saturday, January 1, 2022 | 57947447 | 529000000 |
| Sunday, January 1, 2023 | 97944000 | 604000000 |
| Monday, January 1, 2024 | 187077000 |
Unlocking the unknown
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) investment is a critical driver of innovation and growth. Over the past decade, Axsome Therapeutics, Inc. and Bausch Health Companies Inc. have demonstrated contrasting strategies in their R&D expenditures.
From 2014 to 2023, Axsome Therapeutics increased its R&D spending by over 2,000%, peaking in 2023 with a remarkable 98 million USD. This surge underscores Axsome's commitment to pioneering new treatments and expanding its therapeutic portfolio. In contrast, Bausch Health maintained a more consistent R&D investment, averaging around 460 million USD annually, with a notable peak of 604 million USD in 2023.
This comparison highlights the diverse approaches within the industry: Axsome's aggressive growth strategy versus Bausch's steady investment, each reflecting their unique market positions and long-term objectives.
Who Prioritizes Innovation? R&D Spending Compared for Bristol-Myers Squibb Company and Bausch Health Companies Inc.
R&D Insights: How Gilead Sciences, Inc. and Axsome Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Zoetis Inc. vs Axsome Therapeutics, Inc.
Comparing Innovation Spending: Teva Pharmaceutical Industries Limited and Axsome Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Viatris Inc. vs Axsome Therapeutics, Inc.
Pharming Group N.V. or Axsome Therapeutics, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Grifols, S.A. vs Axsome Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Grifols, S.A. and Bausch Health Companies Inc.
Axsome Therapeutics, Inc. or ADMA Biologics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Bausch Health Companies Inc. vs Viridian Therapeutics, Inc.